Transient restless legs syndrome after spinal anesthesia: a prospective study.

Transdermal rotigotine for the perioperative management of restless legs syndrome. BMC Neurol (2012) 0.75

Transient restless legs syndrome after spinal anesthesia: A prospective study. Neurology (2003) 0.75

Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27

The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81

Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation (2001) 2.82

Environmental risk factors for REM sleep behavior disorder: a multicenter case-control study. Neurology (2012) 2.54

Prediction of recovery from post-traumatic vegetative state with cerebral magnetic-resonance imaging. Lancet (1998) 2.44

Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study) BMJ (1996) 2.42

Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry (2002) 2.36

Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer (2005) 2.33

Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation (1997) 2.18

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet (2005) 2.18

Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology (2003) 1.90

Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia (2006) 1.87

Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology (2005) 1.77

Juvenile asymmetric segmental spinal muscular atrophy (Hirayama's disease): three cases without evidence of "flexion myelopathy". Acta Neurol Scand (2001) 1.74

Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry (2000) 1.70

The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg (2001) 1.69

Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. Eur J Neurol (2012) 1.57

Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry (1999) 1.57

Effects of phenylephrine on the sublingual microcirculation during cardiopulmonary bypass. Br J Anaesth (2009) 1.56

Subacute dementia and imaging correlates in a case of Fahr's disease. J Neurol Neurosurg Psychiatry (2004) 1.53

EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol (2013) 1.52

Intrathecal steroids to reduce pain after lumbar disc surgery: a double-blind, placebo-controlled prospective study. Pain (1995) 1.52

Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol (2001) 1.52

The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol (2002) 1.51

Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother (2001) 1.50

Distal myasthenia gravis frequency and clinical course in a large prospective series. Acta Neurol Scand (2003) 1.50

Long-term outcome of children with acute cerebellitis. Neuropediatrics (2012) 1.50

Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain (1999) 1.48

Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology (2007) 1.48

Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation (1999) 1.46

Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology (2002) 1.46

Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology (2008) 1.45

Effects of epinephrine on intestinal oxygen supply and mucosal tissue oxygen tension in pigs. Crit Care Med (2001) 1.45

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol (2006) 1.45

Free asymmetric dimethylarginine (ADMA) is low in children and adolescents with classical phenylketonuria (PKU). J Inherit Metab Dis (2012) 1.45

Subcutaneous apomorphine in Parkinson's disease. Lancet (1988) 1.41

Inotropic treatment and intestinal mucosal tissue oxygenation in a model of porcine endotoxemia. Crit Care Med (1997) 1.40

[Vascular parkinsonian syndrome]. Nervenarzt (2006) 1.39

[Spinal fibrocartilaginous embolism]. Nervenarzt (2005) 1.39

Cortical and brain stem hyperexcitability in striatonigral degeneration. Mov Disord (1998) 1.38

Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage (2000) 1.32

A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke (2000) 1.31

Influence of concurrent tasks on gait: a dual-task approach. Percept Mot Skills (1995) 1.31

The PRIPS study: screening battery for subjects at risk for Parkinson's disease. Eur J Neurol (2012) 1.29

Tachyarrhythmias in a surgical intensive care unit: a case-controlled epidemiologic study. Intensive Care Med (2000) 1.25

Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology (2003) 1.25

Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry (1998) 1.25

Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol (2013) 1.24

Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry (2004) 1.22

Levodopa in the treatment of Parkinson's disease. Eur J Neurol (2009) 1.21

Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry (2004) 1.19

Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep (2002) 1.19

A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut (2003) 1.19

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry (1997) 1.17

Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord (2000) 1.17

Weight change and cancer risk in a cohort of more than 65,000 adults in Austria. Ann Oncol (2007) 1.17

External stabilization of long-segment tracheobronchomalacia guided by intraoperative bronchoscopy. Ann Thorac Surg (1997) 1.17

Botulinum toxin in writer's cramp: objective response evaluation in 31 patients. J Neurol Neurosurg Psychiatry (1996) 1.16

Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology (2011) 1.15

Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm (Vienna) (2002) 1.15

The natural course of Sneddon syndrome: clinical and magnetic resonance imaging findings in a prospective six year observation study. J Neurol Neurosurg Psychiatry (2003) 1.14

Comparative analysis of gait in Parkinson's disease, cerebellar ataxia and subcortical arteriosclerotic encephalopathy. Brain (1999) 1.14

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol (2006) 1.13

Directional bias of initial visual exploration. A symptom of neglect in Parkinson's disease. Brain (1996) 1.13

Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. Eur J Nucl Med (2000) 1.11

Clinical and polymyographic investigation of spasmodic torticollis. J Neurol (1992) 1.11

Temporal profile and cell subtype distribution of activated caspase-3 following experimental traumatic brain injury. J Neurochem (2000) 1.10

Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol (2001) 1.08

In vitro studies on the activity of amphotericin B and lipid-based amphotericin B formulations against Aspergillus conidia and hyphae. Mycoses (2002) 1.08

Replication of restless legs syndrome loci in three European populations. J Med Genet (2009) 1.08

Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol (1995) 1.08

Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med (2002) 1.07

Strong genetic evidence for association of TOR1A/TOR1B with idiopathic dystonia. Neurology (2006) 1.07

Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. Eur J Cancer (2001) 1.07

Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med (1997) 1.06

Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med (2013) 1.06

The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm (Vienna) (2005) 1.05

Hemimasticatory spasm in hemifacial atrophy: diagnostic and therapeutic aspects in two patients. Mov Disord (1995) 1.05

Closed reduction transarticular Kirschner wire fixation versus open reduction internal fixation in the treatment of Bennett's fracture dislocation. J Hand Surg Br (2003) 1.04

Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord (1997) 1.04

The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol (2013) 1.03

Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord (1999) 1.02

Clinical characteristics of the geste antagoniste in cervical dystonia. J Neurol (2001) 1.02

Trick maneuvers in cervical dystonia: investigation of movement- and touch-related changes in polymyographic activity. Mov Disord (1999) 1.02

How to diagnose MSA early: the role of magnetic resonance imaging. J Neural Transm (Vienna) (2005) 1.01

Magnetic resonance imaging in the diagnosis of spinal cord diseases. J Neurol Neurosurg Psychiatry (1985) 1.01